<SEC-DOCUMENT>0001437749-18-022243.txt : 20181219
<SEC-HEADER>0001437749-18-022243.hdr.sgml : 20181219
<ACCEPTANCE-DATETIME>20181219073658
ACCESSION NUMBER:		0001437749-18-022243
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181219
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181219
DATE AS OF CHANGE:		20181219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KEMPHARM, INC
		CENTRAL INDEX KEY:			0001434647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				205894398
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36913
		FILM NUMBER:		181242213

	BUSINESS ADDRESS:	
		STREET 1:		1180 CELEBRATION BOULEVARD, SUITE 103
		CITY:			CELEBRATION
		STATE:			FL
		ZIP:			34747
		BUSINESS PHONE:		(321) 939-3416

	MAIL ADDRESS:	
		STREET 1:		1180 CELEBRATION BOULEVARD, SUITE 103
		CITY:			CELEBRATION
		STATE:			FL
		ZIP:			34747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KEMPHARM INC
		DATE OF NAME CHANGE:	20080507
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kmph20181218_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
<head>
	<title>kmph20170106_8k.htm</title>

</head>
<body style="font-family: Times New Roman, Times, serif; margin-right: 10px; margin-left: 10px; cursor: auto;"><!-- Created by RDG HTML Converter -->
<hr style="margin: 3pt 0px; border: currentColor; border-image: none; width: 100%; height: 3px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<hr style="margin: 0px 0px 3pt; border: currentColor; border-image: none; width: 100%; height: 1px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 18pt;"><b>UNITED STATES</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 18pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>WASHINGTON, D.C. 20549 </b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<hr style="margin: 3pt auto; border: currentColor; border-image: none; width: 25%; height: 1px; text-align: center; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 18pt;"><b>FORM 8-K </b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<hr style="margin: 3pt auto; border: currentColor; border-image: none; width: 25%; height: 1px; text-align: center; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>CURRENT REPORT </b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Date of Report (Date of Earliest Eve</b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>nt Reported):&nbsp;December 19</b><b>, 2018</b></font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<hr style="margin: 3pt auto; border: currentColor; border-image: none; width: 25%; height: 1px; text-align: center; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 24pt;"><b>KemPharm, Inc.</b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Exact Name of Registrant as Specified in Its Charter) </b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<hr style="margin: 3pt auto; border: currentColor; border-image: none; width: 25%; height: 1px; text-align: center; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL10" style="width: 100%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Delaware</b></p>
			</td>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>001-36913</b></p>
			</td>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>20-5894398</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(State or Other Jurisdiction of Incorporation)</b></p>
			</td>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Commission File Number)</b></p>
			</td>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(IRS Employer Identification No.)</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 33.3%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 33.3%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>1180 Celebration Boulevard, Suite 103</b></p>

			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Celebration, FL</b></p>
			</td>
			<td style="width: 33.3%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>34747</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Address of Principal Executive Offices)</b></p>
			</td>
			<td style="width: 33.3%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 33.3%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Zip Code)</b></p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Registrant<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&rsquo;s Telephone Number, Including Area Code: </font></b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(321) 939-3416</b></font></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Not Applicable </b></p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(Former Name or Former Address, if Changed Since Last Report) </b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<hr style="margin: 3pt auto; border: currentColor; border-image: none; width: 25%; height: 1px; text-align: center; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB11" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 24pt; vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&#9744;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB12" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 24pt; vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&#9744;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB13" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 24pt; vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&#9744;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB14" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 24pt; vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&#9744;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect; 240.12b-2 of this chapter).</p>

<p style="margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Emerging growth company&nbsp;&nbsp; &#9746;</p>

<p style="margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp; &#9746;</p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Item 7</b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>.01</b><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><b>Regulation FD Disclosure</b><b>.</b></font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 18pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On December 19, 2018, KemPharm, Inc. issued a press release to provide a corporate update on the ongoing partnering process for its co-lead clinical development product candidates intended for the treatment of attention-deficit/hyperactivity disorder, KP415 and KP484.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and is not incorporated by reference into any of the Company&rsquo;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Financial Statements and Exhibits.</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="MTAB15" style="width: 100%; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 27pt; vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">(d)</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibits</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL16" style="width: 100%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 10.6%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;No.</font></p>
			</td>
			<td style="width: 1.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 87.5%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">Description</p>
			</td>
		</tr>
		<tr>
			<td style="width: 10.6%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">99.1</p>
			</td>
			<td style="width: 1.9%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 87.5%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;"><a href="ex_131846.htm" style="-sec-extract: exhibit;">Press Release titled <font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&ldquo;</font>KemPharm&nbsp;Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&rdquo; dated&nbsp;December 19, 2018.</font></a></p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>SIGNATURES</b></p>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: Times New Roman, Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" id="TBL17" style="width: 100%; text-indent: 0px; font-family: Times New Roman, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 45.4%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="width: 49.6%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Kem</b><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Pharm</b></font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>, Inc</b></font><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>.</b></font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: middle;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.2%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 46.4%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Date: December 19<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">, 2018</font></p>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.2%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">By:</p>
			</td>
			<td style="width: 46.4%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">/s/ R. LaDuane Clifton</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.2%; vertical-align: middle;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>
			</td>
			<td style="width: 46.4%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">R. LaDuane Clifton</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45.4%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 3.2%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>
			</td>
			<td style="width: 46.4%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">Chief Financial<font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"> Officer, Secretary and Treasurer</font></p>
			</td>
		</tr>

</table>

<p style="font-family: Times New Roman, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_131846.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
	<title>ex99-1.htm</title>

</head>
<body style="font-family: Times New Roman, Times, serif; margin-right: 10px; margin-left: 10px; cursor: auto;">
<div style="text-align: right;"><b>Exhibit 99.1</b></div>

<div style="text-align: right;">&nbsp;</div>

<div><img src="logo.jpg"></div>
<!-- Created by RDG HTML Converter -->

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;"><b>KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio</b></p>

<p style="margin: 0pt 7.5pt; text-align: center; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;"><b>Celebration, FL &ndash; December 19, 2018 &ndash;</b> KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today provided a corporate update on the ongoing partnering process for its co-lead clinical development product candidates intended for the treatment of attention-deficit/hyperactivity disorder (ADHD), KP415 and KP484.&nbsp; Both KP415 and KP484 are based on a prodrug of d-methylphenidate, and have been designed with differing extended-duration profiles.&nbsp;</p>

<p style="margin: 0pt 7.5pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">&ldquo;As we first announced in August, we have been working through a formal partnering process for our ADHD assets, KP415 and KP484, and to date, we have generated a significant amount of interest,&rdquo; said Travis Mickle, Ph.D., President and Chief Executive Officer of KemPharm.&nbsp; &ldquo;A number of companies have signed confidentiality agreements with us and have been conducting due diligence.&nbsp; From these efforts, we have received multiple early offers and indications of interest from both strategic and financial partners.&nbsp; Our next step is to undertake a second round of discussions over the coming weeks with the parties that have indicated interest in partnering the ADHD assets, and with other parties that may come forward, as we seek to maximize shareholder value in finding the right partner and commercialization strategy for these product candidates.&rdquo;</p>

<p style="margin: 0pt 7.5pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">Dr. Mickle continued, &ldquo;The interest in our ADHD product candidates was not a surprise to us based on our understanding of market dynamics and the ability of our prodrug approach to potentially meet key unmet needs voiced by prescribers and patients.&nbsp; We remain emboldened by market research and the insights of ADHD opinion leaders that the potential for KP415 and KP484 to provide early onset of action, longer duration of therapy and lower abuse potential, has the potential to position both product candidates as differentiated methylphenidate products within the high-demand ADHD treatment landscape.&nbsp; Although the partnering process will not be completed by year-end, and we cannot predict the ultimate result, we are encouraged by the activity level we have seen and believe that extending the process timeline is a strategic decision that will yield the best outcome for shareholders.&rdquo;</p>

<p style="margin: 0pt 7.5pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;"><b>About KemPharm:</b></p>

<p style="font-family: 'Times New Roman', Times, Serif; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT&trade; (Ligand Activated Therapy) technology.&nbsp; KemPharm utilizes its proprietary LAT technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.&nbsp; KemPharm&rsquo;s product pipeline is focused on the high need areas of ADHD, pain, and other central nervous system disorders.&nbsp; Its co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of d-methylphenidate, but with differing extended-duration profiles intended for the treatment of ADHD.&nbsp; In addition, KemPharm has received FDA approval for APADAZ<sup>&reg;</sup>, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.&nbsp; For more information on KemPharm and its pipeline of prodrug product candidates visit <u>www.kempharm.com</u> or connect with us on <u>Twitter</u>, <u>LinkedIn</u>, <u>Facebook</u> and <u>YouTube</u>.</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;"><b>Caution Concerning Forward Looking Statements:</b></p>

<p style="font-family: 'Times New Roman', Times, Serif; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.&nbsp; Forward-looking statements include statements about KemPharm&rsquo;s plans to partner its ADHD assets and its views about the potential for those plans, and all other statements that do not relate solely to historical or current facts, and can be identified by the use of words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;potential,&rdquo; &ldquo;should,&rdquo; &ldquo;continue&rdquo; or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm&rsquo;s business are described in detail in KemPharm&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2017, and KemPharm&rsquo;s other Periodic and Current Reports filed with the Securities and Exchange Commission.&nbsp; KemPharm is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.</p>

<p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="margin: 0pt; width: 100%; text-indent: 0px; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">

		<tr style="font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">
			<td style="width: 45.3%; font-family: 'Times New Roman', Times, Serif; font-size: 11pt; vertical-align: top;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;"><b>Investor Contacts:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b></p>
			</td>
			<td style="width: 54.6%; font-family: 'Times New Roman', Times, Serif; font-size: 11pt; vertical-align: top;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">
			<td style="width: 45.3%; font-family: 'Times New Roman', Times, Serif; font-size: 11pt; vertical-align: top;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">Jason Rando / Joshua Drumm, Ph.D.</p>

			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;"><u>Tiberend Strategic Advisors, Inc.</u></p>

			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">212-375-2665 / 2664</p>

			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;"><u>jrando@tiberend.com</u></p>

			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;"><u>jdrumm@tiberend.com</u></p>
			</td>
			<td style="width: 54.6%; font-family: 'Times New Roman', Times, Serif; font-size: 11pt; vertical-align: top;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, Serif; font-size: 11pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: center; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M0HQ'&HPD8]%':EUG3SI6L7-FW2)R%)[KU!_+%4LU^$5JDX7HVY4GJO-=^_\
M5C],I0A*U6]V]GY/MV_JX4 $D #))P .]&:[GP)X:\UUU>^3Y%/^CH1U/]__
M  JL'A*F+K*E#Y^2%B\3#"TG4G_P[-SP=X;&C6/VBZ3_ $V=?FS_ ,LU_N_X
MUTM%%?IN'P]/#TE2IK1'YU7KSQ%1U)[L****W,0HHHH **** "BBB@ HHHH
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B^.CJ-R+I6!^R[5\OB+R^O7IS7=T8JK"IR<O2*7S"*L?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
